Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

Three drug combinations, ipilimumab-nivolumab (Ipi-Nivo), pembrolizumab-axitinib (Pembro-Axi), and avelumab-axitinib (Ave-Axi), have received regulatory approval in the USA and Europe for the treatment of metastatic renal cell carcinoma with clear cell component (mRCC). However, no head-to-head comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Elaidi, Reza, Phan, Letuan, Borchiellini, Delphine, Barthelemy, Philippe, Ravaud, Alain, Oudard, Stéphane, Vano, Yann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352474/
https://www.ncbi.nlm.nih.gov/pubmed/32599839
http://dx.doi.org/10.3390/cancers12061673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352474/
https://www.ncbi.nlm.nih.gov/pubmed/32599839
http://dx.doi.org/10.3390/cancers12061673

Ejemplares similares